CENTOCOR WILL BEGIN CENTORx RESTENOSIS STUDY BY APRIL
CENTOCOR WILL BEGIN CENTORx RESTENOSIS STUDY BY APRIL, President and CEO David Holveck reported during a March 9 teleconference for investors and analysts. The trial will study the thrombolytic monoclonal antibody CentoRx (7E3) in 2,100 angioplasty patients at various levels of risk for complications. Endpoints will be assessed at six months. Lilly has rights to CentoRx under a 1992 agreement with Centocor.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth